A synergy recognized in the control of inflammation and repair of severe tissue damage.
BioSenic and its mission
BioSenic is an innovative company with the objective of addressing important unmet medical needs in the areas of innate immunity, inflammation and organ/function repair.
Our expertise is focused on cell therapy and the therapeutic use of arsenic trioxide (As2O3). BioSenic aims to become a leading company in the field of regenerative and immune medicine by developing innovative products for and autoimmune and inflammatory diseases.
BioSenic has a broad and diverse portfolio of solutions in clinical development in a variety of therapeutic areas targeting markets characterized by significant unmet medical needs and limited innovation.
- MORE
-
Our technology is based on two approaches:
Arsenic Trioxide : an innovative drug to treat autoimmune diseases at the source of the immune cascade. Medical arsenic is a small inorganic molecule with a strong therapeutic impact on pro-inflammatory responses. It modulates innate immunity and pro- and anti-inflammatory pathways with a dual mechanism of action:
- ROS-induced apoptosis of overactivated B and T cells.
- Reduction of the production of pro-inflammatory cytokines
ALLOB ® : a unique and proprietary approach to bone regeneration that transforms undifferentiated stem cells into "osteoblastic" or bone tissue reconstitution cells. The administration of these cells is performed in a minimally invasive manner, thus avoiding cumbersome surgical procedures.
Our lead clinical program:
cGVHD - Chronic Graft versus Host Disease.
For this indication, a Phase II study has already shown positive results: the first-line combination of arsenic trioxide and prednisone in cGVHD showed an overall response rate (ORR) at 6 months of 75%, which allows for a rapid reduction in corticosteroids
Medsenic is now finalizing the preparation of a Phase III trial. This study will be a randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of oral arsenic trioxide (OATO) as a first-line treatment. The oral formulation, known as OATO - or ARSCICOR for autoimmune applications - has the characteristics of rapid gastrointestinal solubilization, optimal bioavailability comparable to the intravenous formulation (ARSCIMED, used in Phase II)
A positive Pre IND opinion from the FDA has been issued to initiate a Phase III clinical trial in this disease.
Executive team
Jean-Luc
Vandebroek
Managing Director (ad interim), Executive Director – permanent representative of Finsys Management SRL
Jean-Luc Vandebroek has extensive experience in large listed and private companies. Jean-Luc's career was built over 15 years at Delhaize (now Ahold Delhaize), the Belgian-American retail group. During this period, he held various positions of increasing responsibility within the finance department, such as CFO Europe and USA, and Vice President Finance Belgium and Luxembourg. He was then promoted to CFO of Fluxys, the listed European gas infrastructure operator. In this role, he was responsible for the financing of large infrastructure projects in the capital markets. Prior to joining Bone Therapeutics and then BioSenic, Jean-Luc was Director and CFO of Moteo Two Wheels and Bihr Europe, the two-wheeler specialist, a subsidiary of the Alcopa Group, a Belgian family-owned holding company with a turnover of around 1.7 billion euros.
Board of Directors
BioSenic is committed to implementing the highest processes and standards of corporate governance, while ensuring that its business model is relevant, efficient and cost effective to the Company and its investors.
The Board of Directors is made up of the Chairman, four non-executive Directors and two executive Directors.
Eric
Halioua
Chairman of the Board of Directors, Independent Director – permanent representative of CarKath SRL
Mr. Eric Halioua is an experienced executive with over 25 years in the life sciences sector, combining scientific expertise with strategic business acumen. Throughout his career, he has demonstrated his ability to create, finance, and lead innovative biotechnology companies. His governance experience and independent judgment will be key assets in guiding BioSenic’s strategy, supporting informed decision-making, and safeguarding shareholders’ interests.
Jean-Luc
Vandebroek
Managing Director (ad interim), Executive Director – permanent representative of Finsys Management SRL
Jean-Luc Vandebroek has extensive experience in large listed and private companies. Jean-Luc's career was built over 15 years at Delhaize (now Ahold Delhaize), the Belgian-American retail group. During this period, he held various positions of increasing responsibility within the finance department, such as CFO Europe and USA, and Vice President Finance Belgium and Luxembourg. He was then promoted to CFO of Fluxys, the listed European gas infrastructure operator. In this role, he was responsible for the financing of large infrastructure projects in the capital markets. Prior to joining Bone Therapeutics and then BioSenic, Jean-Luc was Director and CFO of Moteo Two Wheels and Bihr Europe, the two-wheeler specialist, a subsidiary of the Alcopa Group, a Belgian family-owned holding company with a turnover of around 1.7 billion euros.
Revital
Rattenbach
Ms. Revital Rattenbach (Aflalo), Non-Executive Director – permanent representative of Iryl Partners SAS
A seasoned biotech entrepreneur with over 15 years of experience, Revital Rattenbach is the CEO and founder of 4P Pharma, a clinical-stage biotech company specializing in active drug regeneration for the treatment of severe diseases. Under her leadership, 4P Pharma has established a unique, circular drug development platform that has brought two programs to the clinic while building a rich preclinical pipeline. Revital has initiated numerous academic and pharmaceutical collaborations worldwide and has completed a series of fundraising events since 4P Pharma was founded 8 years ago. Previously, Revital was the Managing Director and Founder of PharmaSeed Europe (2013-2014), a research organization focused on early stage development, where she oversaw all activities related to business development, finance and operations. Revital began her entrepreneurial career by co-founding Astem, a Sorbonne University spin-off specializing in endogenous adult stem cell activation. She holds a PhD in biology from the University of Paris VI and an MBA from the Sorbonne University.
Jean-François
Rax
Non-Executive Director – permanent representative of Capital Grand Est SAS
An engineer with a degree in Biochemistry and Biotechnology from INSA Lyon, Jean-François joined Capital Grand Est in 2014, an independent regional private equity company approved by the AMF with more than €180M in assets under management and which has been supporting more than 60 SMEs and start-ups in the Grand Est region since 2012. With 12 years of experience in venture & seed capital - 4 years in consulting and technology transfer - Inserm Transfert Initiative, Alcimed, Inra Transfert, Inserm Transfert, Jean-François is now a member of the Board of Directors / Director of Investments of Capital Grand Est.
Anne-Sophie
Jourdain
Independent Director
Ms. Anne-Sophie Jourdain is an expert in strategy and business law, with over 20 years of experience in various sectors such as retail, services, insurance, and new technologies. Currently Director in charge of legal affairs, governance, taxation, compliance, and insurance within a large international group, she sits on management committees and is involved in strategic projects in France and internationally, including development, mergers and acquisitions, and structural partnerships. She has in-depth expertise in corporate strategy, which she uses to support organizational transformation and manage complex operations. She has led numerous restructuring projects and implemented robust compliance and data protection policies. Trained in mediation, she also acts as a mediator, contributing to the amicable resolution of disputes. She also serves as a commercial court judge, which attests to her legitimacy and commitment to serving the public interest. In addition, she holds several board member positions, where she brings her strategic vision, risk management expertise, and operational experience to governance bodies.
Seppe
De Gelas
Independent Director – permanent representative of Boletus Consulting BV
Mr. Seppe De Gelas is a seasoned expert in quality assurance (QA) and regulatory affairs (RA), with over 25 years of international experience in the pharmaceutical, medical device, and tissue sectors. His career combines practical technical expertise, leadership in innovative biopharmaceutical companies, entrepreneurship, and university teaching. A chemist by training and specializing in the field of peptides, he began his professional career in clinical research at Bristol-Myers Squibb, before moving on to QA and RA roles at Baxter, UCB, and Lonza, where he oversaw regulatory compliance, quality systems, and manufacturing controls. From 2010 to 2015, he ran his own GMP laboratory, performing quality control testing and batch release for the European market, before founding Boletus Consulting to advise SMEs and large companies on integrated QA and RA strategies for active ingredients, drugs, and medical devices. One of his major projects was as director of QA and regulatory affairs for a start-up specializing in implantable medical devices designed to continuously monitor blood glucose levels using photonic technology. He currently serves as Vice President of Quality Assurance and Regulatory Affairs at a publicly traded pharmaceutical company in the EU specializing in 505(b)(2) procedures. In this role, he has been instrumental in developing optimized, digitally-enabled quality systems and supporting regulatory submissions. Since 2017, Seppe has also been teaching European regulatory affairs, process control, and process validation as part of the international biomedical regulatory sciences program at the University of Georgia College of Pharmacy (Atlanta, USA). His academic work covers global regulatory frameworks, with a focus on FDA and EMA requirements.
BioSenic SA
Avenue Léon champagne, 3
1480 Saintes – Belgium
info@biosenic.com